Mission

Nanotechnological Toolkits for Multi-Modal Disease Diagnostics and Treatment Monitoring (NAMDIATREAM) will develop a cutting-edge, nanotechnology-based toolkit for multi-modal detection of biomarkers of most common cancer types and cancer metastases, permitting identification of cells indicative of early disease onset in a high-specificity and throughput format in clinical, laboratory, and point-of-care devices. The project is built on the innovative concepts of super-sensitive and highly specific “lab-on-a-bead,”“lab-on-a-chip,” and “lab-on-a-wire” nano-devices utilizing photoluminescent, plasmonic, magnetic, and nonlinear optical properties of nanomaterials. This offers groundbreaking advantages over present technologies in terms of stability, sensitivity, time of analysis, probe multiplexing, assay miniaturization, and reproducibility. The ETP in Nanomedicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer. More than 3.2 million new cases and 1.7 million cancer-related deaths are registered in Europe every year, largely because diagnostic methods have an insufficient level of sensitivity, limiting their potential for early disease identification.

NAMDIATREAM will deliver the following:

Financing

NAMDIATREAM is co-funded by the European Community under the Seventh Framework Programme.

Impact/Accomplishment

NAMDIATREAM has successfully developed a nanotechnology-based toolkit to enable early detection and imaging of molecular biomarkers of the most common cancer types (e.g., breast, lung, and prostate) and of cancer metastases, as well as permitting the identification of cells indicative of early-stage disease onset. The project is built on the innovative technology concepts of super-sensitive “lab-on-a-bead,” “lab-on-a-chip,” and “lab-on-a-wire” nano-devices.

NAMDIATREAM has delivered photoluminescent nanoparticle-based reagents and diagnostic chips for high-throughput early diagnosis of cancer and treatment. They allow for identification of true “molecular signatures” of specific biomarkers and cancer cells within diagnostic material. The validation of these nano-tools has been carried out in compliance with the OECD regulatory policies in nano-materials.

Links/Social Media Feed

Points of Contact

Administrative Contact
Deirdre Savage
phone: +35318961942
fax: +35317071633

Sponsors & Partners